company background image
6660 logo

AIM Vaccine SEHK:6660 Stock Report

Last Price

HK$8.13

Market Cap

HK$9.8b

7D

1.4%

1Y

-81.5%

Updated

29 Mar, 2024

Data

Company Financials +

6660 Stock Overview

AIM Vaccine Co., Ltd. engages in the research and development, manufacturing, and commercialization of vaccine products for human use in the People’s Republic of China.

6660 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance0/6
Financial Health2/6
Dividends0/6

AIM Vaccine Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AIM Vaccine
Historical stock prices
Current Share PriceHK$8.13
52 Week HighHK$55.40
52 Week LowHK$6.06
Beta0
1 Month Change20.09%
3 Month Change3.57%
1 Year Change-81.48%
3 Year Changen/a
5 Year Changen/a
Change since IPO-51.20%

Recent News & Updates

Recent updates

Investor Optimism Abounds AIM Vaccine Co., Ltd. (HKG:6660) But Growth Is Lacking

Jun 09
Investor Optimism Abounds AIM Vaccine Co., Ltd. (HKG:6660) But Growth Is Lacking

Shareholder Returns

6660HK BiotechsHK Market
7D1.4%-2.3%-1.5%
1Y-81.5%-41.4%-13.9%

Return vs Industry: 6660 underperformed the Hong Kong Biotechs industry which returned -41.4% over the past year.

Return vs Market: 6660 underperformed the Hong Kong Market which returned -13.9% over the past year.

Price Volatility

Is 6660's price volatile compared to industry and market?
6660 volatility
6660 Average Weekly Movement9.0%
Biotechs Industry Average Movement9.9%
Market Average Movement7.4%
10% most volatile stocks in HK Market14.7%
10% least volatile stocks in HK Market3.7%

Stable Share Price: 6660 has not had significant price volatility in the past 3 months.

Volatility Over Time: 6660's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20111,572Yan Zhouhttps://www.aimbio.com

AIM Vaccine Co., Ltd. engages in the research and development, manufacturing, and commercialization of vaccine products for human use in the People’s Republic of China. The company’s product pipeline includes Bivalent Delta-Omicron BA.5 mRNA and Monovalent Omicron BA.5 mRNA, which is in phase III clinical trails for the treatment of COVID-19; EV71-CA16 Bivalent for HFMD; and Valent Pneumococcal Conjugate and Polysaccharide vaccine for pneumococcal disease. It also offers Hexavalent group B Streptococcus Polysaccharide Conjugate Vaccine for Group B strep disease; Diphtheria, Tetanus and Pertussis and Haemophilus In¬uenzae type B, and Diphtheria, Tetanus and Acellular Pertussis, and Absorbed Tetanus for DTP; Haemophilus In¬uenzae Type B for Hib; and freeze-dried human rabies and mRNA human rabies vaccine.

AIM Vaccine Co., Ltd. Fundamentals Summary

How do AIM Vaccine's earnings and revenue compare to its market cap?
6660 fundamental statistics
Market capHK$9.85b
Earnings (TTM)-HK$1.41b
Revenue (TTM)HK$1.29b

7.7x

P/S Ratio

-7.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6660 income statement (TTM)
RevenueCN¥1.19b
Cost of RevenueCN¥286.45m
Gross ProfitCN¥901.02m
Other ExpensesCN¥2.20b
Earnings-CN¥1.30b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.07
Gross Margin75.88%
Net Profit Margin-109.56%
Debt/Equity Ratio45.3%

How did 6660 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.